This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Petitclerc, E. Articles by C.-Gaudreault, R. Search for Related Content PubMed PubMed Citation Articles by Petitclerc, E. Articles by C.-Gaudreault, R.

Antiangiogenic and Antitumoral Activity of Phenyl-3-(2-Chloroethyl)Ureas

A Class of Soft Alkylating Agents Disrupting Microtubules That Are Unaffected by Cell Adhesion-Mediated Drug Resistance

¹ Centre de Recherche, Unité de Biotechnologie et de Bioingénierie, CHUQ, Hôpital Saint-François d’Assise, Québec, Québec, Canada; ² Département de Médecine, Faculté de Médecine, Université Laval, Sainte-Foy, Québec, Québec, Canada; ³ Département des Sciences Fondamentales, Université du Québec à Chicoutimi, Québec, Québec, Canada; and ⁴ Institut National de la Santé et de la Recherche Médicale U484, Clermont-Ferrand, Cédex, France

The development of new anticancer agents with lower toxicity, higher therapeutic index, and weaker tendency to induce resistant phenotypes in tumor cells is a continuous challenge for the scientific community. Toward that end, we showed previously that a new class of soft alkylating agents designed as phenyl-3-(2-chloroethyl)ureas (CEUs) inhibits tumor cell growth in vitro and that their efficiency is not altered by clinically relevant mechanisms of resistance such as overexpression of multidrug resistance proteins, increase in intracellular concentration of glutathione and/or glutathione S-transferase activity, alteration of topoisomerase II, and increased DNA repair. Mechanistic studies have showed recently that the cytotoxic activity of several CEUs was mainly related to the disruption of microtubules. Here, we present results supporting our assumption that 4-tert-butyl-[3-(2-chloroethyl)ureido]phenyl (tBCEU) (and its bioisosteric derivative 4-iodo-[3-(2-chloroethyl)ureido]phenyl (ICEU) are potent antimicrotubule agents both in vitro and in vivo. They covalently bind to ß-tubulin, leading to a microtubule depolymerization phenotype, consequently disrupting the actin cytoskeleton and altering the nuclear morphology. Accordingly, tBCEU and ICEU also inhibited the migration and proliferation of endothelial and tumor cells in vitro in a dose-dependent manner. It is noteworthy that ICEU efficiently blocked angiogenesis and tumor growth in three distinct animal models: (a) the Matrigel plug angiogenesis assay; (b) the CT-26 tumor growth assay in mice; and (c) the chick chorioallantoic membrane tumor assay. In addition, we present evidence that CEU cytotoxicity is unaffected by additional resistance mechanisms impeding tumor response to DNA alkylating agents such as cisplatin, namely the cell adhesion mediated-drug resistance mechanism, which failed to influence the cytocidal activity of CEUs. On the basis of the apparent innocuousness of CEUs, on their ability to circumvent many classical and recently described tumor cell resistance mechanisms, and on their specific biodistribution to organs of the gastrointestinal tract, our results suggest that CEUs represent a promising new class of anticancer agents.

This article has been cited by other articles:

				A. Patenaude, R. G. Deschesnes, J. L.C. Rousseau, E. Petitclerc, J. Lacroix, M.-F. Cote, and R. C.-Gaudreault New Soft Alkylating Agents with Enhanced Cytotoxicity against Cancer Cells Resistant to Chemotherapeutics and Hypoxia Cancer Res., March 1, 2007; 67(5): 2306 - 2316. [Abstract] [Full Text] [PDF]

				R. G. Deschesnes, A. Patenaude, J. L. C. Rousseau, J. S. Fortin, C. Ricard, M.-F. Cote, J. Huot, R. C.-Gaudreault, and E. Petitclerc Microtubule-Destabilizing Agents Induce Focal Adhesion Structure Disorganization and Anoikis in Cancer Cells J. Pharmacol. Exp. Ther., February 1, 2007; 320(2): 853 - 864. [Abstract] [Full Text] [PDF]

				B. Bouchon, C. Chambon, E. Mounetou, J. Papon, E. Miot-Noirault, R. C. Gaudreault, J.-C. Madelmont, and F. Degoul Alkylation of {beta}-Tubulin on Glu 198 by a Microtubule Disrupter Mol. Pharmacol., November 1, 2005; 68(5): 1415 - 1422. [Abstract] [Full Text] [PDF]

				V. K.W. Wong, P. Chiu, S. S.M. Chung, L. M.C. Chow, Y.-Z. Zhao, B. B. Yang, and B. C.B. Ko Pseudolaric Acid B, a Novel Microtubule-Destabilizing Agent That Circumvents Multidrug Resistance Phenotype and Exhibits Antitumor Activity In vivo Clin. Cancer Res., August 15, 2005; 11(16): 6002 - 6011. [Abstract] [Full Text] [PDF]